Stockwatch: The Victimization Of Big Biotech
Early Success In Biotech Raises An Almost Impossible Bar
Alexion is a case study in the travails faced by a biotech with a single blockbuster as it tries to maintain its scale and transform itself into a sustainable business, without blowing billions on bad M&A.
You may also be interested in...
Roche Mounts NMOSD Challenge To Alexion’s Soliris
Satralizumab will be boosted by convenience and MS portfolio in increasingly competitive field.
Stock Watch: Defeat Is The Mother Of Reinvention
Companies that are successful do not need to change their name, therapeutic area or product focus.
Stock Watch: Orphan Drug Profitability Under Threat
The difficulty of finding and retaining patients with orphan diseases translates into higher marketing costs and adds to other restrictions that limit the attractiveness of some orphan drugs. Will the IRA exacerbate matters?